Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

BACKGROUND: High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, F, Wei, X L, Wang, F H, Xu, N, Shen, L, Dai, G H, Yuan, X L, Chen, Y, Yang, S J, Shi, J H, Hu, X C, Lin, X Y, Zhang, Q Y, Feng, J F, Ba, Y, Liu, Y P, Li, W, Shu, Y Q, Jiang, Y, Li, Q, Wang, J W, Wu, H, Feng, H, Yao, S, Xu, R H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771223/
https://www.ncbi.nlm.nih.gov/pubmed/31236579
http://dx.doi.org/10.1093/annonc/mdz197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771223/
https://www.ncbi.nlm.nih.gov/pubmed/31236579
http://dx.doi.org/10.1093/annonc/mdz197

Ejemplares similares